The omics perspective on heart failure research
10.16438/j.0513-4870.2020-0251
- VernacularTitle:心力衰竭研究的组学视角
- Author:
Jin-yue ZHANG
1
;
Qi-feng LIU
1
;
Liu YANG
1
;
Xue-qi LÜ
1
;
Ying-hong WANG
1
Author Information
1. State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
- Publication Type:Research Article
- Keywords:
heart failure;
biomarker;
omics analysis technique;
multi-omics analysis;
heart failure therapy
- From:
Acta Pharmaceutica Sinica
2020;55(5):832-842
- CountryChina
- Language:Chinese
-
Abstract:
Heart failure is the end stage of many cardiovascular diseases. It seriously affects the safety and quality of life of nearly 40 million people worldwide. At present, the clinical and pathophysiological characteristics of some types of heart failure are unknown, and there is no effective diagnosis and treatment. In recent years, genomics, transcriptomics, epigenomics, proteomics, metabolomics and other omics technologies have been widely used in disease research, providing new opportunities for the prevention, diagnosis and treatment of diseases. These strategies have also brought hope for the reduction in heart failure mortality. Based on the current status of clinical treatment of heart failure, this article reviews the roles and potential applications of these various omics technologies and their opportunities in the study of the pathogenesis of heart failure, clinical diagnosis and treatment, and related drug pharmacodynamics and mechanism of action.
